1. Real world data (RWD) collected outside clinical trials reflects outcomes in the real world. Real world evidence (RWE) generated from RWD can help understand effectiveness, maximize value for payers, and manage uncertainty given evolving research and development. 2. Managed entry agreements (MEAs) are used to formally incorporate RWD to manage product entry addressing uncertainty while maximizing payer value through performance-linked reimbursement or coverage with evidence development. 3. Challenges to the use of RWE include implementation burdens, governance of data collection and analysis, and methodological issues in dealing with less controlled real world data.